CAPITOL COUNSEL LLC

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Pharmaceutical manufacturer.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Massachusetts · $30,000.00 income · posted Jan 18, 2026

Lobbying activity 1

Medical/Disease Research/Clinical Labs

Issues regarding FDA guidance on Platform Technology Platform Technology Designation Program for Drug Development.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.